Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Conversion Therapy of Sintilimab Combined With Bevacizumab and XELOX/SOX for Initially Unresectable AFP-positive Gastric/Esophagogastric Junction Adenocarcinoma : A Multi-center, Single-arm, Phase II Trial (SOLIDS-02)

NCT07515625 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07515625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07515625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Conversion Therapy of Sintilimab Combined With Bevacizumab and XELOX/SOX for Initially Unresectable AFP-positive Gastric/Esophagogastric Junction Adenocarcinoma : A Multi-center, Single-arm, Phase II Trial (SOLIDS-02)
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
April 1, 2029
Enrollment
46 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

afp gastric or gastroesophageal junction adenocarcinoma, gastric cancer (gc)